Immunitybio Inc (IBRX)
Healthcare
Biotechnology
7.20 $
-3.8%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Immunitybio Inc (IBRX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 37.6% of the shares are freely tradable; institutional investors hold 17.6%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
17.6%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
62.5%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
37.6%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
34.8%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
1,047Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Group Inc | 3.13 | 32,777,257 | +18.5 | 12/31/2025 |
| BlackRock Inc | 2.52 | 26,346,443 | +2.9 | 03/31/2026 |
| State Street Corp | 1.69 | 17,708,103 | +7.6 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 1.56 | 16,322,844 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 1.44 | 15,127,714 | +0.0 | 03/31/2026 |
| D. E. Shaw & Co LP | 1.20 | 12,571,597 | +0.0 | 03/31/2026 |
| Geode Capital Management, LLC | 0.77 | 8,031,921 | +1.4 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 1.10 | 11,480,900 | +1.2 | 04/30/2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.08 | 11,340,495 | -0.6 | 05/31/2026 |
| Vanguard Small Cap Index | 0.79 | 8,292,147 | -0.1 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.